Canaccord Genuity set a $155.00 price objective on Laboratory Corp. of America Holdings (NYSE:LH) in a report issued on Wednesday morning. The firm currently has a a buy rating on the stock.

Other research analysts also recently issued research reports about the company. KeyCorp restated a buy rating and set a $143.00 price target on shares of Laboratory Corp. of America Holdings in a report on Sunday, May 22nd. Zacks Investment Research upgraded Laboratory Corp. of America Holdings from a hold rating to a buy rating and set a $143.00 price target on the stock in a report on Tuesday, May 17th. SunTrust Banks Inc. restated a buy rating on shares of Laboratory Corp. of America Holdings in a report on Thursday, July 28th. Evercore ISI boosted their price target on Laboratory Corp. of America Holdings from $147.00 to $155.00 and gave the company a buy rating in a report on Wednesday, July 27th. Finally, Barclays PLC set a $155.00 price target on Laboratory Corp. of America Holdings and gave the company a buy rating in a report on Monday, August 29th. Eight research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $140.86.

Laboratory Corp. of America Holdings (NYSE:LH) opened at 135.01 on Wednesday. The firm has a 50-day moving average price of $137.88 and a 200 day moving average price of $128.45. The company has a market cap of $13.81 billion, a price-to-earnings ratio of 22.42 and a beta of 0.85. Laboratory Corp. of America Holdings has a one year low of $97.79 and a one year high of $141.32.

Laboratory Corp. of America Holdings (NYSE:LH) last released its quarterly earnings data on Wednesday, July 27th. The company reported $2.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.30 by $0.01. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.33 billion. Laboratory Corp. of America Holdings had a return on equity of 17.01% and a net margin of 6.64%. The company’s quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.09 earnings per share. Equities analysts expect that Laboratory Corp. of America Holdings will post $8.81 earnings per share for the current fiscal year.

In other Laboratory Corp. of America Holdings news, insider Lisa J. Uthgenannt sold 1,177 shares of the stock in a transaction dated Tuesday, August 9th. The shares were sold at an average price of $140.00, for a total transaction of $164,780.00. Following the completion of the transaction, the insider now owns 3,660 shares of the company’s stock, valued at approximately $512,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Glenn A. Eisenberg sold 8,000 shares of the stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $140.10, for a total transaction of $1,120,800.00. Following the transaction, the chief financial officer now directly owns 8,668 shares of the company’s stock, valued at approximately $1,214,386.80. The disclosure for this sale can be found here. 1.14% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LH. Macquarie Group Ltd. increased its position in Laboratory Corp. of America Holdings by 1,290.0% in the second quarter. Macquarie Group Ltd. now owns 27,800 shares of the company’s stock valued at $3,622,000 after buying an additional 25,800 shares during the period. Kentucky Retirement Systems Insurance Trust Fund bought a new position in Laboratory Corp. of America Holdings during the second quarter valued at approximately $539,000. Kentucky Retirement Systems bought a new position in Laboratory Corp. of America Holdings during the second quarter valued at approximately $1,134,000. Northwestern Mutual Investment Management Company LLC increased its position in Laboratory Corp. of America Holdings by 0.6% in the second quarter. Northwestern Mutual Investment Management Company LLC now owns 3,905 shares of the company’s stock valued at $509,000 after buying an additional 22 shares during the period. Finally, Mason Street Advisors LLC bought a new position in Laboratory Corp. of America Holdings during the second quarter valued at approximately $1,797,000. 92.11% of the stock is owned by institutional investors and hedge funds.

Laboratory Corp. of America Holdings Company Profile

Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

5 Day Chart for NYSE:LH

Receive News & Ratings for Laboratory Corp. of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.